Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB25FL1P8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $164,083
Award facts
- Contract value 100% obligated
- $164,083.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $164,083.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The contract utilizes firm fixed-price pricing with an ultimate completion date of August 13, 2025, and represents a delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA. This award carries no set-aside designation, demonstrating the contractor's competitive strength in the federal pharmaceutical procurement marketplace. The product will be supplied to the Park Ridge, Illinois location for distribution to Department of Defense healthcare facilities.
DMS Pharmaceutical Group holds a substantial single-award IDC with DLA valued at $499,999,999 and valid through November 2026 under the SPE2DB program, which enables the issuance of firm fixed-price delivery orders for pharmaceutical products supporting military health facilities worldwide. As a certified woman-owned small business registered in SAM.gov since 2001, the contractor has established itself as a critical supplier in the federal pharmaceutical supply chain, with a robust portfolio of delivery orders covering an extensive range of branded and generic prescription drugs, biologics, and medical consumables including oncology treatments, vaccines, and specialty medications. This delivery order for Keytruda, an oncology treatment, reflects DMS Pharmaceutical Group's established capabilities in supplying high-value pharmaceutical products to Department of Defense healthcare systems.
Quick answers
Who was awarded contract SPE2DB25FL1P8?
SPE2DB25FL1P8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 23, 2025.
How much is contract SPE2DB25FL1P8 worth?
The government has obligated $164,083 on SPE2DB25FL1P8.
Is contract SPE2DB25FL1P8 an order under another contract?
Yes. SPE2DB25FL1P8 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB25FL1P8 competed?
The extent of competition for SPE2DB25FL1P8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award